Ascendis Pharma A/S - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ASND Nasdaq 2836 ascendispharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascendis Pharma A/S

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 - Aug 6th, 2026 2:01 pm
European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading - Aug 6th, 2026 9:18 am
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. - Aug 6th, 2026 6:00 am
European Equities Traded in US as ADRs Advance in Tuesday Trading - Aug 4th, 2026 9:06 am
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns - Jul 24th, 2026 9:03 am
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo - Jul 14th, 2026 8:42 am
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia - Jul 12th, 2026 6:07 am
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24% - Jul 12th, 2026 12:11 am
Why Crinetics Stock Soared 99% This Week - Jul 9th, 2026 11:29 am
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading - Jul 8th, 2026 9:09 am
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial - Jun 30th, 2026 6:30 am
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® - Jun 26th, 2026 2:01 pm
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last? - Jun 26th, 2026 8:45 am
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 - Jun 25th, 2026 2:01 pm
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism - Jun 13th, 2026 2:00 pm
European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week - Jun 12th, 2026 9:14 am
Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years - Jun 11th, 2026 2:35 pm
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism - Jun 11th, 2026 2:01 pm
Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy - Jun 9th, 2026 5:22 pm
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - Jun 8th, 2026 2:59 pm